Literature DB >> 21912721

A gut feeling about murine syngeneic GVHD.

J Scott Bryson1, J Anthony Brandon, C Darrell Jennings, Alan M Kaplan.   

Abstract

Murine syngeneic graft-versus-host disease (SGVHD) results in chronic colon and liver inflammation following syngeneic bone marrow transplantation (BMT) and treatment with the calcineurin inhibitor, cyclosporine A (CsA). SGVHD was initially thought to arise as a result of an autoreactive immune response, but more recently it has been shown that enhanced antimicrobial responses develop in SGVHD mice. Consequently, we performed studies to analyze the role of the microbiota in the development of murine SGVHD. Treatment with broad-spectrum antibiotics eliminated disease-associated inflammatory immune responses and pathology, linking the role of the microbiota and microbial-specific immunity to the development of murine SGVHD. In a broader context, these results bring into question the role that anti-microbial immune responses play in post-transplant immune pathologies that develop following allogeneic stem cell transplantation and use of calcineurin inhibitors.

Entities:  

Year:  2011        PMID: 21912721      PMCID: PMC3166486          DOI: 10.4161/chim.2.2.16783

Source DB:  PubMed          Journal:  Chimerism        ISSN: 1938-1964


  22 in total

Review 1.  Immuno-bacterial homeostasis in the gut: new insights into an old enigma.

Authors:  C O Elson; Y Cong; N Iqbal; C T Weaver
Journal:  Semin Immunol       Date:  2001-06       Impact factor: 11.130

2.  Enteric bacterial antigens activate CD4(+) T cells from scid mice with inflammatory bowel disease.

Authors:  J Brimnes; J Reimann; M Nissen; M Claesson
Journal:  Eur J Immunol       Date:  2001-01       Impact factor: 5.532

3.  Role of bacterial microflora in development of intestinal lesions from graft-versus-host reaction.

Authors:  D W van Bekkum; S Knaan
Journal:  J Natl Cancer Inst       Date:  1977-03       Impact factor: 13.506

4.  The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506.

Authors:  M H Cooper; G G Hartman; T E Starzl; J J Fung
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

5.  Development of a T(H)17 immune response during the induction of murine syngeneic graft-versus-host disease.

Authors:  J Anthony Brandon; C Darrell Jennings; Alan M Kaplan; J Scott Bryson
Journal:  Cytokine       Date:  2010-09-15       Impact factor: 3.861

6.  Murine syngeneic graft-versus-host disease is responsive to broad-spectrum antibiotic therapy.

Authors:  J Anthony Brandon; C Darrell Jennings; Alan M Kaplan; J Scott Bryson
Journal:  J Immunol       Date:  2011-02-04       Impact factor: 5.422

7.  Association between chronic liver and colon inflammation during the development of murine syngeneic graft-versus-host disease.

Authors:  J Anthony Brandon; Jacqueline Perez; C Darrell Jennings; Donald A Cohen; V J Sindhava; S Bondada; Alan M Kaplan; J Scott Bryson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-07-15       Impact factor: 4.052

8.  Adoptive transfer of murine syngeneic graft-vs.-host disease by CD4+ T cells.

Authors:  J Scott Bryson; C Darrell Jennings; Jason A Brandon; Jacqueline Perez; Betty E Caywood; Alan M Kaplan
Journal:  J Leukoc Biol       Date:  2007-08-28       Impact factor: 4.962

9.  CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease.

Authors:  Y Cong; S L Brandwein; R P McCabe; A Lazenby; E H Birkenmeier; J P Sundberg; C O Elson
Journal:  J Exp Med       Date:  1998-03-16       Impact factor: 14.307

10.  An antibiotic-responsive mouse model of fulminant ulcerative colitis.

Authors:  Silvia S Kang; Seth M Bloom; Lyse A Norian; Michael J Geske; Richard A Flavell; Thaddeus S Stappenbeck; Paul M Allen
Journal:  PLoS Med       Date:  2008-03-04       Impact factor: 11.069

View more
  1 in total

Review 1.  Prevention of graft-vs.-host disease.

Authors:  Andrew R Rezvani; Rainer F Storb
Journal:  Expert Opin Pharmacother       Date:  2012-07-07       Impact factor: 3.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.